May 1 (UPI) --Pharmaceutical giant Johnson & Johnson on Wednesday said it is taking steps to resolve a multibillion dollar, cancer-related lawsuit with thousands of individuals over claims that ...
Johnson & Johnson is pursuing a “plan of reorganization” aimed at resolving 99.75% of the 60,000-plus talcum powder lawsuits the company faces. While that $6.5 billion settlement plan would ...
Benzinga - by Vandana Singh, Benzinga Editor. Wednesday, Johnson & Johnson (NYSE:JNJ) announced its intention to proceed with a $6.475 billion settlement to resolve numerous lawsuits related to ...
A group of cancer victims sued Johnson & Johnson on Wednesday, accusing the healthcare company of committing fraud through repeated and continued efforts to use a shell company's bankruptcy to ...
OREGON – Johnson & Johnson (J&J) must pay US$260 million (S$350 million) to an Oregon woman who said she got mesothelioma – a deadly cancer linked to asbestos exposure – from inhaling the ...
A jury has ruled that Johnson & Johnson JNJ must pay $260 million to an Oregon woman who claims to have developed mesothelioma from using the company’s talc powder. What Happened: The jury’s ...
Investing in J&J offers potential dividend income with 61 years of consecutive increases. J&J plans to spin off its consumer division, focusing on pharmaceuticals and medical technology.
Shawn Johnson and husband Andrew East have experienced several firsts together since tying the knot in 2016, but taking in the Olympics as a family has not yet been one of them. That will change ...
May 13 (UPI) --U.S.-based Red Lobster abruptly closed more than 50 of its seafood restaurants across the country on Monday, as the company is reported to be considering Chapter 11 bankruptcy ...
Shelby is an editor with an affinity for covering home improvement and repair, design and real estate trends. She also specializes in content strategy and entrepreneur coaching for small ...
Benzinga - by Vandana Singh, Benzinga Editor. On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 study of TAR-210 in patients with ...